Insider · CIK 0001920553
Kristian Reich
Files at MLTX (MoonLake Immunotherapeutics). First filing Feb 16, 2024, latest Jul 29, 2026.
In brief
Kristian Reich files SEC Form 4 as officer at MLTX (MoonLake Immunotherapeutics). Since Feb 16, 2024, Kristian Reich has reported 0 open-market buys worth $0 and 9 open-market sells worth $20M, the latest filed on Jul 29, 2026.
A track record needs three past buys with six months of prices behind them; Kristian Reich has 0, so none is measured yet.
The newest scored trade: sold $22k of MLTX on Jul 27, 2026, filed Jul 29, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $8.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MLTX: MoonLake Immunotherapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | MoonLake Immunotherapeutics | $22k 1,100 shares | -0% | +218% from low-68% from high | |
| 28Weak | MoonLake Immunotherapeutics | $1.0M 52,448 shares | -2% | +221% from low-68% from high | |
| 26Weak | MoonLake Immunotherapeutics | $878k 43,700 shares | -2% | +205% from low-69% from high | |
| 17Weak | MoonLake Immunotherapeutics | $322k 16,105 shares | -1% | +220% from low-68% from high | |
| 28Weak | MoonLake Immunotherapeutics | $2.9M 150,000 shares | -5% | +207% from low-69% from high | |
| 68Notable | MoonLake Immunotherapeutics | $3.0M 202,908 shares | -100% | - | |
| 28Weak | MoonLake Immunotherapeutics | $6.5M 118,922 shares | -4% | +193% from low-14% from high | |
| 28Weak | MoonLake Immunotherapeutics | $1.2M 21,078 shares | -1% | +210% from low-14% from high | |
| 28Weak | MoonLake Immunotherapeutics | $3.7M 60,000 shares | -2% | +272% from low-2% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 15, 2026 | MLTX MoonLake Immunotherapeutics | 150,000 0.20% of outstanding | $2.9M | Jul 15, 2026 | $2.9M |
| Jun 15, 2026 | MLTX MoonLake Immunotherapeutics | 150,000 0.20% of outstanding | $2.9M | Jun 15, 2026 | none |
| Dec 8, 2025 | MLTX Moonlake Immunotherapeutics | 202,908 0.32% of outstanding | $3.0M | Dec 8, 2025 | none |
| Feb 14, 2024 | MLTX MoonLake Immunotherapeutics | 200,000 0.33% of outstanding | $13M | Feb 14, 2024 | none |
Transactions
Every row this insider has filed, 31 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -1,100 | $20.00 | $22k | 2,711,198 | Jul 29, 2026 |
| Jul 21, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $20.02 | $1.0M | 2,714,746 | Jul 23, 2026 |
| Jul 22, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -2,448 | $20.00 | $49k | 2,712,298 | Jul 23, 2026 |
| Jul 20, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -43,700 | $20.09 | $878k | 2,764,746 | Jul 21, 2026 |
| Jul 15, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -16,105 | $20.01 | $322k | 2,808,446 | Jul 20, 2026 |
| Jun 15, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $18.89 | $945k | 2,924,551 | Jun 17, 2026 |
| Jun 16, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $18.70 | $935k | 2,874,551 | Jun 17, 2026 |
| Jun 17, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $19.43 | $972k | 2,824,551 | Jun 17, 2026 |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | AGrant or award Stock Option (Right to Buy)derivative | +520,342 | $0.00 | $0 | 520,342 | Jan 9, 2026 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Class A ordinary shares, par value $0.0001 per share | +35,389 | - | - | 35,389 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -35,389 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -1,052 | - | - | 0 | Dec 22, 2025 |
| Dec 8, 2025 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -130,000 | $15.08 | $2.0M | 72,908 | Dec 10, 2025 |
| Dec 9, 2025 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -72,908 | $14.43 | $1.1M | 0 | Dec 10, 2025 |
| Sep 2, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Class A ordinary shares, par value $0.0001 per share | +48,978 | - | - | 202,908 | Sep 4, 2025 |
| Sep 2, 2025 | MLTX MoonLake Immunotherapeutics | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -48,978 | - | - | 35,389 | Sep 4, 2025 |
| Jan 20, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -1,456 | - | - | 1,052 | Sep 4, 2025 |
| Feb 27, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -29,491 | $55.00 | $1.6M | 2,957,483 | Feb 29, 2024 |
| Feb 27, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -29,431 | $55.00 | $1.6M | 70,071 | Feb 29, 2024 |
| Feb 28, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -31,910 | $55.00 | $1.8M | 2,925,573 | Feb 29, 2024 |
| Feb 28, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -28,090 | $55.00 | $1.5M | 41,981 | Feb 29, 2024 |
| Feb 20, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -10,000 | $57.45 | $575k | 2,987,483 | Feb 22, 2024 |
| Feb 20, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -10,000 | $57.43 | $574k | 100,071 | Feb 22, 2024 |
| Feb 21, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -509 | $55.31 | $28k | 2,986,974 | Feb 22, 2024 |
| Feb 21, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -569 | $55.30 | $31k | 99,502 | Feb 22, 2024 |
| Feb 14, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -10,000 | $62.42 | $624k | 3,017,483 | Feb 16, 2024 |
| Feb 14, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -10,000 | $62.43 | $624k | 130,071 | Feb 16, 2024 |
| Feb 15, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -10,000 | $60.17 | $602k | 3,007,483 | Feb 16, 2024 |
| Feb 15, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -10,000 | $60.16 | $602k | 120,071 | Feb 16, 2024 |
| Feb 16, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -10,000 | $60.15 | $602k | 2,997,483 | Feb 16, 2024 |
| Feb 16, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -10,000 | $60.15 | $602k | 110,071 | Feb 16, 2024 |
Questions about Kristian Reich
Answered from the filings on this page, as of the latest one.
Is Kristian Reich buying or selling?
In the last 12 months Kristian Reich reported 0 open-market buys worth $0 and 6 open-market sells worth $8.1M on SEC Form 4; the latest was sold $22k of MLTX on Jul 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Kristian Reich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kristian Reich has 0.
Where does Kristian Reich file Form 4?
Kristian Reich has filed Form 4 at MLTX (MoonLake Immunotherapeutics) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.